AN2 Therapeutics extends Gates Foundation funding for TB research with GSK

The company said the Gates Foundation awarded an extension of funding to support its ongoing tuberculosis research collaboration with GSK. The work focuses on boron-based leucyl-tRNA synthetase inhibitors.